Tonix Pharma - רווח למניה לשנה מתגלגלת TNXP

Tonix Pharmaceuticals (TNXP) is currently undergoing a rigorous business model restructuring, concentrating capital on the final stages of drug testing to maintain solvency. This price chart helps track this process, where EPS stands at 98.20. The firm's viability relies on FDA approval for its antiviral and fibromyalgia medications. Additionally, the company is developing joint projects with scientific centers to combat infections and CNS diseases.
TNXP (Tonix Pharma): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The long-term sustainability of Tonix Pharmaceuticals (TNXP) is determined by the business's ability to generate growing earnings per share. The dynamics of this metric measure the rate of change in net income over the last 12 months relative to the previous year. By analyzing the annual EPS (TTM) change on the GURU.Markets platform, an investor identifies systemic capital degradation or growth. For Tonix Pharmaceuticals (TNXP), this confirms the effectiveness of establishing a closed patent portfolio in the CNS field.